London Cancer Hub secures approval for £1bn expansion plans
The London Cancer Hub has secured approval for a £1 billion ($1.4 billion) expansion, bringing state-of-the-art cancer research and lab space to the UK.
London Cancer Hub’s expanded district promises to be one of the world’s most ambitious life sciences clusters, with 12 acres dedicated to accelerating cancer research, treatment and commercial innovation.
The approved expansion, led by Aviva Capital Partners and Socius, is expected to create 3,000 new high-skilled jobs. The wider London Cancer Hub district is projected to support 13,000 jobs in total and contribute £1.2 billion ($1.6 billion) Gross Value Added once fully completed.
The development could play a vital role in helping the UK tackle future health challenges by providing critical science infrastructure that supports innovation, attracts investment and accelerates life-saving discoveries.
The London Cancer Hub is already home to The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, alongside the Innovation Gateway, which supports early-stage life sciences companies.
“We’re delighted to secure planning consent for the London Cancer Hub – a landmark moment for this scheme,” Sophie White, Sector Head Regeneration at Aviva Capital Partners.
“This development will deliver critical science infrastructure for the UK, helping the UK get ready for the future by creating an environment where innovation can flourish and lifesaving research can accelerate. We are proud to play a role in shaping a campus that will have a profound impact on global health, as well as the economy.”
“The London Cancer Hub is about more than buildings,” added Daniel May, Director of Socius.
“We are delivering the next phase of investment into an already world-class cancer district, creating a powerful catalyst for private investment and long-term growth. It’s about creating a vibrant ecosystem where collaboration drives discovery.
“By working closely with the ICR, The Royal Marsden, and our partners, we are delivering a worldclass environment that will support businesses, attract investment, and ultimately improve patient outcomes.”
